MarketLens
Sign Up

What's Driving Rocket Pharmaceuticals' Latest FDA Review for KRESLADI

7 months ago
SHARE THIS ON:

What's Driving Rocket Pharmaceuticals' Latest FDA Review for KRESLADI

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of Gene Therapy for Glycogen Storage Disease Type 1a Transcript

Ultragenyx's gene therapy for glycogen storage disease type 1a received FDA approval, marking a key regulatory milestone. The approval could drive revenue growth if commercial launch executes well.
Stock News•2 months ago

Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus

Rocket Pharmaceuticals' Q2 earnings rose year over year, driven by Kresladi launch preparations and supportive RP-A501 safety findings that advance its development pipeline.
Stock News•2 months ago

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

Dyne Therapeutics' BLA for z-rostudirsen in exon 51 DMD received FDA Priority Review, with a PDUFA date of January 21, 2027, after the DELIVER trial showed statistically significant dystrophin increas...

Breaking News

View All →

Top Headlines

View More →
Stock News•1 hour ago

Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today

Stock News•1 hour ago

Why the Market Dipped But Microsoft (MSFT) Gained Today

Stock News•1 hour ago

Nvidia (NVDA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Stock News•1 hour ago

Tesla (TSLA) Declines More Than Market: Some Information for Investors

Stock News•1 hour ago

Amazon Will Be The Final Winner Of The AI Race With Anthropic's Help